Answers are grounded in this paper and cite their sources.
The search of non-invasive methods of diagnosis of kidney disease, new biomarkers of injury and its level is very important at present time. Such markers are KIM-1 (kidney injury molecule - 1), TGF-β1 (transforming growth factor - β1), RBP (retinol-binding protein) and β2-MG (β2 – microglobulin). β2-MG and RBP are low molecular weight proteins which are rapidly filtered in the glomerulus and catabolized in the renal tubules after resorption by cells of proximal part. These proteins aren't reabsorbed and appear in the urine in the pathology of the tubules. This fact allows using β2-MG and RBP for diagnostics of injury of the proximal tubules. KIM-1 isn't detected in normal kidney tissue. However, the expression level of this biomarker increases significantly on the surface of the epithelial cells of the proximal tubules after ischemic or toxic damage of kidneys. For this reasons KIM-1 is an ideal markers of kidney injury and allows differentiating ischemic damage from prerenal azotemia and chronic kidney disease (CKD). TGF-β1 indicates endothelial dysfunction and fibroangiogenesis which are the basis of remodeling of the microvascular bed of the kidney in various kinds of glomerulopathies. The results of determination of concentration in serum and urine are presented in this article. The introduction of KIM-1, TGF-β1, RBP and β2-MG into clinical practice will expand the possibility of diagnosis of kidney diseases, allow non-invasive monitoring of progression and the effectiveness of nephroprotective therapy.
No takes yet. Share an insight, caveat, or question.
Bialkevich et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: